133 related articles for article (PubMed ID: 9353333)
1. Inhibition of meizothrombin and meizothrombin(desF1) by heparin cofactor II.
Han JH; Côté HC; Tollefsen DM
J Biol Chem; 1997 Nov; 272(45):28660-5. PubMed ID: 9353333
[TBL] [Abstract][Full Text] [Related]
2. The in situ inhibition of prothrombinase-formed human alpha-thrombin and meizothrombin(des F1) by antithrombin III and heparin.
Schoen P; Lindhout T
J Biol Chem; 1987 Aug; 262(23):11268-74. PubMed ID: 3611110
[TBL] [Abstract][Full Text] [Related]
3. Mutagenesis of thrombin selectively modulates inhibition by serpins heparin cofactor II and antithrombin III. Interaction with the anion-binding exosite determines heparin cofactor II specificity.
Sheehan JP; Wu Q; Tollefsen DM; Sadler JE
J Biol Chem; 1993 Feb; 268(5):3639-45. PubMed ID: 8429040
[TBL] [Abstract][Full Text] [Related]
4. Depolymerized holothurian glycosaminoglycan with novel anticoagulant actions: antithrombin III- and heparin cofactor II-independent inhibition of factor X activation by factor IXa-factor VIIIa complex and heparin cofactor II-dependent inhibition of thrombin.
Nagase H; Enjyoji K; Minamiguchi K; Kitazato KT; Kitazato K; Saito H; Kato H
Blood; 1995 Mar; 85(6):1527-34. PubMed ID: 7888673
[TBL] [Abstract][Full Text] [Related]
5. Heparin cofactor II is regulated allosterically and not primarily by template effects. Studies with mutant thrombins and glycosaminoglycans.
Sheehan JP; Tollefsen DM; Sadler JE
J Biol Chem; 1994 Dec; 269(52):32747-51. PubMed ID: 7806495
[TBL] [Abstract][Full Text] [Related]
6. Site-directed mutagenesis of arginine 103 and lysine 185 in the proposed glycosaminoglycan-binding site of heparin cofactor II.
Blinder MA; Tollefsen DM
J Biol Chem; 1990 Jan; 265(1):286-91. PubMed ID: 2104620
[TBL] [Abstract][Full Text] [Related]
7. Thrombin inhibition by HCII in the presence of elastase-cleaved HCII and thrombin-HCII complex.
Maekawa H; Sato H; Tollefsen DM
Thromb Res; 2000 Dec; 100(5):443-51. PubMed ID: 11150588
[TBL] [Abstract][Full Text] [Related]
8. Multiple active forms of thrombin. IV. Relative activities of meizothrombins.
Doyle MF; Mann KG
J Biol Chem; 1990 Jun; 265(18):10693-701. PubMed ID: 2355015
[TBL] [Abstract][Full Text] [Related]
9. Substitution of arginine for Leu444 in the reactive site of heparin cofactor II enhances the rate of thrombin inhibition.
Derechin VM; Blinder MA; Tollefsen DM
J Biol Chem; 1990 Apr; 265(10):5623-8. PubMed ID: 2138609
[TBL] [Abstract][Full Text] [Related]
10. Functional characterization of recombinant human meizothrombin and Meizothrombin(desF1). Thrombomodulin-dependent activation of protein C and thrombin-activatable fibrinolysis inhibitor (TAFI), platelet aggregation, antithrombin-III inhibition.
Côté HC; Bajzar L; Stevens WK; Samis JA; Morser J; MacGillivray RT; Nesheim ME
J Biol Chem; 1997 Mar; 272(10):6194-200. PubMed ID: 9045633
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of heparin cofactor II anticoagulant activity.
Bauman SJ; Church FC
J Biol Chem; 1999 Dec; 274(49):34556-65. PubMed ID: 10574918
[TBL] [Abstract][Full Text] [Related]
12. The N-terminal acidic domain of heparin cofactor II mediates the inhibition of alpha-thrombin in the presence of glycosaminoglycans.
Van Deerlin VM; Tollefsen DM
J Biol Chem; 1991 Oct; 266(30):20223-31. PubMed ID: 1939083
[TBL] [Abstract][Full Text] [Related]
13. The protease specificity of heparin cofactor II. Inhibition of thrombin generated during coagulation.
Parker KA; Tollefsen DM
J Biol Chem; 1985 Mar; 260(6):3501-5. PubMed ID: 3838315
[TBL] [Abstract][Full Text] [Related]
14. The preferred pathway of glycosaminoglycan-accelerated inactivation of thrombin by heparin cofactor II.
Verhamme IM; Bock PE; Jackson CM
J Biol Chem; 2004 Mar; 279(11):9785-95. PubMed ID: 14701814
[TBL] [Abstract][Full Text] [Related]
15. Effect of oligodeoxynucleotide thrombin aptamer on thrombin inhibition by heparin cofactor II and antithrombin.
Holland CA; Henry AT; Whinna HC; Church FC
FEBS Lett; 2000 Nov; 484(2):87-91. PubMed ID: 11068038
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of a thrombin anion-binding exosite-2 mutant by the glycosaminoglycan-dependent serpins protein C inhibitor and heparin cofactor II.
Cooper ST; Rezaie AR; Esmon CT; Church FC
Thromb Res; 2002 Jul; 107(1-2):67-73. PubMed ID: 12413592
[TBL] [Abstract][Full Text] [Related]
17. Antithrombin activity of fucoidan. The interaction of fucoidan with heparin cofactor II, antithrombin III, and thrombin.
Church FC; Meade JB; Treanor RE; Whinna HC
J Biol Chem; 1989 Feb; 264(6):3618-23. PubMed ID: 2914965
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms for inhibition of the generation of thrombin activity by sulfated polysaccharides.
Ofosu FA; Modi GJ; Hirsh J; Buchanan MR; Blajchman MA
Ann N Y Acad Sci; 1986; 485():41-55. PubMed ID: 2436525
[TBL] [Abstract][Full Text] [Related]
19. Formation of meizothrombin as intermediate in factor Xa-catalyzed prothrombin activation.
Rosing J; Zwaal RF; Tans G
J Biol Chem; 1986 Mar; 261(9):4224-8. PubMed ID: 3753979
[TBL] [Abstract][Full Text] [Related]
20. A recombinant murine meizothrombin precursor, prothrombin R157A/R268A, inhibits thrombosis in a model of acute carotid artery injury.
Shim K; Zhu H; Westfield LA; Sadler JE
Blood; 2004 Jul; 104(2):415-9. PubMed ID: 15039280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
